Contents

Tenapanor

Tenapanor

Clinical data
Trade names	Ibsrela, Xphozah, others
Other names	Tenapanor hydrochloride
AHFS/Drugs.com	Monograph
License data	US DailyMed: Tenapanor
Routes of administration	By mouth
Drug class	NHE3 inhibitors
ATC code	A06AX08 (WHO)
Legal status
Legal status	CA: ℞-only[1][2] US: ℞-only[3][4]
Identifiers
IUPAC name N,N'-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis([(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl]benzenesulfonamide)
CAS Number	1234423-95-0
PubChem CID	71587953
DrugBank	DB11761
ChemSpider	32056950
UNII	WYD79216A6 50605O2ZNS
KEGG	D11652 D11653
ChEMBL	ChEMBL3304485
CompTox Dashboard (EPA)	DTXSID40154016
ECHA InfoCard	100.243.471
Chemical and physical data
Formula	C50H66Cl4N8O10S2
Molar mass	1145.04 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1C[C@H](C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)[C@@H]5CN(CC6=C5C=C(C=C6Cl)Cl)C
InChI InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1 Key:DNHPDWGIXIMXSA-CXNSMIOJSA-N

Tenapanor, sold under the brand name Ibsrela among others, is a medication used for the treatment of adults with a disease of the gut called irritable bowel syndrome with constipation commonly referred to as IBS-C.^[3][5] It is used in form of tenapanor hydrochloride.^[3] It is also used in the treatment of chronic kidney disease.^[4] Tenapanor is a sodium hydrogen exchanger 3 (NHE3) inhibitor.^[4]

Tenapanor is a drug developed by Ardelyx, which acts as an inhibitor of the sodium-proton exchanger NHE3. This antiporter protein is found in the kidney and intestines, and normally acts to regulate the levels of sodium absorbed and secreted by the body. When administered orally, tenapanor selectively inhibits sodium uptake in the intestines, limiting the amount absorbed from food, and thereby reduces levels of sodium in the body.^[6] This may make it useful in the treatment of chronic kidney disease and hypertension, both of which are exacerbated by excess sodium in the diet.^[7]

It was approved for medical use in the United States in September 2019.^[3][8][5][9] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[10] In October 2023, tenapanor was approved by the FDA for the treatment of hyperphosphatemia.^[11]

References[edit]

^ ^{a b} "Drug Trials Snapshots: Ibsrela". U.S. Food and Drug Administration (FDA). 27 September 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019. This article incorporates text from this source, which is in the public domain.

External links[edit]

• Clinical trial number NCT02686138 for "A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)" at ClinicalTrials.gov
• Clinical trial number NCT02621892 for "A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)" at ClinicalTrials.gov
• Clinical trial number NCT02675998 for "An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)" at ClinicalTrials.gov
• Clinical trial number NCT03427125 for "A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis" at ClinicalTrials.gov
• Clinical trial number NCT03824587 for "Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy" at ClinicalTrials.gov

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.